Akebia plummets as it abandons Vafseo for non-dialysis patients
Source: SeekingAlpha
2025-10-28 17:45:05 ET
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
- Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection
- Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
- Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches
- Akebia Q2 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Akebia plummets as it abandons Vafseo for non-dialysis patients
Akebia Therapeutics Inc.
NASDAQ: AKBA
AKBA Trading
2.89% G/L:
$1.425 Last:
2,079,511 Volume:
$1.41 Open:
AKBA Latest News
March 03, 2026 08:00:00 am
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026 07:00:00 am
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
AKBA Stock Data
$399,375,819
257,405,013
0.93%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
